OBJECTIVE: This study examined the course of illness in patients with obsessive-compulsive disorder (OCD) over a 2-year period. METHOD: Sixty-six patients with a primary diagnosis of DSM-III-R OCD were followed prospectively for 2 years. Baseline information was collected on demographic characteristics, Axis I and II diagnoses, and severity of OCD symptoms. Follow-up measures obtained at 3, 6, 12, and 24 months after baseline assessment included information on symptomatic and diagnostic status as well as behavioral and somatic treatments received. RESULTS: The probability of full remission from OCD over the 2-year period was 12%. The probability of partial remission was 47%. After achieving remission from OCD, the probability of relapse was 48%. No factors were identified that significantly predicted full or partial remission. Seventy-seven percent (N = 51) of the subjects received a serotonin reuptake inhibitor (SRI) for > or =12 weeks, and 68% (N = 45) received medium-to-high doses of SRIs for > or =12 weeks. Only 18% received a full trial of behavior therapy. CONCLUSION: Despite exposure to at least 1 adequate trial of an SRI, the likelihood of full remission of OCD in this study was low. Results of this study also suggest that behavior therapy may be under-utilized.
OBJECTIVE: This study examined the course of illness in patients with obsessive-compulsive disorder (OCD) over a 2-year period. METHOD: Sixty-six patients with a primary diagnosis of DSM-III-R OCD were followed prospectively for 2 years. Baseline information was collected on demographic characteristics, Axis I and II diagnoses, and severity of OCD symptoms. Follow-up measures obtained at 3, 6, 12, and 24 months after baseline assessment included information on symptomatic and diagnostic status as well as behavioral and somatic treatments received. RESULTS: The probability of full remission from OCD over the 2-year period was 12%. The probability of partial remission was 47%. After achieving remission from OCD, the probability of relapse was 48%. No factors were identified that significantly predicted full or partial remission. Seventy-seven percent (N = 51) of the subjects received a serotonin reuptake inhibitor (SRI) for > or =12 weeks, and 68% (N = 45) received medium-to-high doses of SRIs for > or =12 weeks. Only 18% received a full trial of behavior therapy. CONCLUSION: Despite exposure to at least 1 adequate trial of an SRI, the likelihood of full remission of OCD in this study was low. Results of this study also suggest that behavior therapy may be under-utilized.
Authors: Nicholas J Sibrava; Christina L Boisseau; Maria C Mancebo; Jane L Eisen; Steven A Rasmussen Journal: Depress Anxiety Date: 2011-08-04 Impact factor: 6.505
Authors: Maria C Mancebo; Christina L Boisseau; Sarah L Garnaat; Jane L Eisen; Benjamin D Greenberg; Nicholas J Sibrava; Robert L Stout; Steven A Rasmussen Journal: Compr Psychiatry Date: 2014-04-24 Impact factor: 3.735
Authors: Samuel J House; Shanti P Tripathi; Bettina T Knight; Natalie Morris; D Jeffrey Newport; Zachary N Stowe Journal: Arch Womens Ment Health Date: 2015-07-16 Impact factor: 3.633
Authors: Brian L Odlaug; Eric Weinhandl; Maria C Mancebo; Erik L Mortensen; Jane L Eisen; Steven A Rasmussen; Liana R N Schreiber; Jon E Grant Journal: Ann Clin Psychiatry Date: 2014-02 Impact factor: 1.567